Cardiac Troponin Serum Concentration Measurement Is Useful Not Only in the Diagnosis of Acute Cardiovascular Events

Journal of Personalized Medicine, Journal Year: 2024, Volume and Issue: 14(3), P. 230 - 230

Published: Feb. 21, 2024

Cardiac troponin serum concentration is the primary marker used for diagnosis of acute coronary syndrome. Moreover, measurement cardiac important risk stratification in patients with pulmonary embolism. The level also a general myocardial damage, regardless etiology. purpose this study to conduct literature review and present most information regarding current state knowledge on chronic cardiovascular disease (CVD), as well relationships between features subclinical dysfunction. According research conducted date, CVDs, such syndrome, lower extremities' ischemia, cerebrovascular disease, are characterized by higher concentrations than people without CVD. data indicate that correlated markers dysfunction system, intima-media thickness, pulse wave velocity, ankle-brachial index, artery calcium index (the Agatston score), flow-mediated dilation. However, further needed various patient subpopulations different clinical contexts.

Language: Английский

---

Endocrinological toxicities related to immunotherapy combinations for advanced renal cell carcinoma: practical expert-based management recommendations

Critical Reviews in Oncology/Hematology, Journal Year: 2025, Volume and Issue: unknown, P. 104627 - 104627

Published: Feb. 1, 2025

Language: Английский

---

CD99 is a potential diagnostic and immunological biomarker in pan-cancer

Research Square (Research Square), Journal Year: 2025, Volume and Issue: unknown

Published: April 18, 2025

Background As a cell adhesion factor, cluster of differentiation 99 (CD99) mainly plays role in regulating differentiation. Recent studies have revealed an important for CD99 the initiation and progression several cancers. However, comprehensive pan-cancer analysis has not been performed. Methods In this study, we utilized advanced bioinformatics techniques to conduct in-depth investigation expression across diverse tumors, its prognostic diagnostic implications, predominant modes genetic alteration, correlations with immune infiltration checkpoints, enrichment analyses related gene expression, mechanisms drug resistance. Results Our findings that was significantly upregulated numerous common cancers associated both outcomes. Notably, alterations predominantly manifested as deletions. Furthermore, exhibited strong nearly all infiltrating cells their corresponding checkpoints. Enrichment further emphasized potential epithelial-mesenchymal transition (EMT) pathways leukocyte migration. Additionally, our investigations into resistance indicated primarily linked against antitumor agents such 5-fluorouracil belinostat. Conclusions Through analysis, elucidated novel roles various cancer types, providing insights clinical treatment strategies development.

Language: Английский

---

A Case in Which HLA-DR4 is Involved in the Development of Complex Immune-Related Endocrinological Adverse Events following Combination Therapy with Nivolumab and Ipilimumab

Case Reports in Endocrinology, Journal Year: 2024, Volume and Issue: 2024, P. 1 - 6

Published: March 22, 2024

Immune checkpoint inhibitors (ICIs) have become a focal point in cancer immunotherapy, though their utilization is also linked to the occurrence of diverse immune-related adverse events (irAEs). Herein, we present details 42-year-old woman diagnosed with malignant vaginal melanoma who underwent ICI therapy combination nivolumab and ipilimumab. Approximately two months after initiating therapy, patient manifested destructive thyroiditis fulminant type 1 diabetes mellitus, thus necessitating intensive insulin therapy. Following onset adrenocorticotropic hormone deficiency, frequent hypoglycemic episodes prompted initiation replacement hydrocortisone. Human leukocyte antigen (HLA)-DNA typing revealed presence HLA-DRB1 ${}^{\ast }$ 04 : 05 DQB1 id="M2">

Language: Английский

---

Research Advances of Immune Checkpoint Inhibitors Related Endocrine Adverse Events

Advances in Clinical Medicine, Journal Year: 2024, Volume and Issue: 14(02), P. 2706 - 2716

Published: Jan. 1, 2024

Language: Английский

---

Levels of serum lipids predict responses to PD-L1 inhibitor as first-line treatment in small cell lung cancer: an observational study

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: April 30, 2024

Background There has not been a definite study on the relationship between serum lipid and small cell lung cancer (SCLC) patients’ response to programed death-ligand 1 (PD-L1) inhibitor. Objective The aim of this was explore association lipids levels SCLC PD-L1 inhibitor as first-line treatment. Methods This included patients with who received at least one cycle PD-L1inhibitor Shanghai Pulmonary Hospital from August 2020 December 2023. We collected clinical data patients, including basic information levels, before immunotherapy. Results Overall, 124 were in study. incidence immune related adverse events (irAEs) 16.1%. In multivariate analyzes, TG/HDL-C ratio remarkable independent predictor irAEs (HR: 16.427, 95% CI: 1.046-258.092, p=0.046). Tumor analysis indicated that an objective rate (ORR) achieved 43.4% disease control (DCR) 79.5%. Seventy-seven experienced any progression-free survival (PFS) event. median PFS longer HDL-C-high group (10.03 months) than HDL-C-low (6.67 (p=0.043). Cox regression analyses, HDL-C for 2.814, 1.413-5.602, p=0.003). Notably, ORR significantly differed suffered those did (p=0.0062). Conclusion clarified might predict responses anti-PD-L1 treatment SCLC.

Language: Английский

---

Hypoparathyroidism update

Current Opinion in Endocrinology Diabetes and Obesity, Journal Year: 2024, Volume and Issue: unknown

Published: May 17, 2024

Purpose of review Since the release 2022 Second International Workshop Evaluation and Management Hypoparathyroidism Summary Statement Guidelines, updates advances are now available in cause, complications, treatment adult chronic hypoparathyroidism (hypoPTH). This aims to highlight these new findings implications patient care. Recent Postsurgical remains most common immune-related from checkpoint inhibitors is an emerging autoimmune cause. In a large retrospective cohort study thyroidectomies, incident fracture was lower, particularly vertebra, hypoPTH cohort, compared with postthyroidectomy control group. Hypercalciuria increases risk for renal calculi independent disease duration dose. Quality life impaired patients on conventional therapy, improvement noted post-PTH replacement. TranCon PTH phase 3 RCT reported eucalcemia reduced calcium excretion, normalization bone turn-over markers, stable BMD improved quality life. HypoPTH associated significant morbidity poor Life. Awareness targets follow-up investigations can alleviate anxiety regarding over-treatment under-treatment. Progress long-acting replacement strategies might provide accessible, feasible alternatives therapy brittle patients.

Language: Английский

---

Levels of serum lipids predict responses to PD-L1 inhibitors as first-line treatment in small cell lung cancer: an observational study

International Journal of Clinical Pharmacy, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 12, 2024

Immunotherapy provides new hope to individuals with small cell lung cancer (SCLC). Predicting biomarkers for clinical effects is crucial SCLC patients receiving programed death-ligand 1 (PD-L1) inhibitor treatment.

Language: Английский

---

Use pembrolizumab may cause acute and severe adverse reactions: a case report and review

International Journal of Surgery Oncology, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 8, 2024

Introduction: Immune checkpoint inhibitors (ICIs) have emerged as pivotal therapeutics for personalized cancer treatment. Programmed death protein receptor 1/ligand 1 (PD-1/PD-L1) represent the most extensively utilized immune blockade agents. Among these, pembrolizumab has gained approval advanced management. By engaging with PD-1 on T cells, orchestrates response against tumor cells; however, it is also associated a spectrum of adverse events, including an infrequent manifestation fulminant type diabetes. Case presentation: ICIs-induced diabetes mellitus (FT1DM) in breast patients been rarely documented. To provide further evidence such this paper presents case 58-year-old Chinese patient and multi-organ metastasis, who had no prior history Following five courses pembrolizumab, she developed severe accompanied by ketoacidosis. Discussion: Pembrolizumab commonly treatment cancer. While offers significant benefits to patients, can lead numerous reactions, immune-related being prevalent among them result usage. Conclusions: FT1DM complicated ketoacidosis represents critical potentially life-threatening medical condition, necessitating immediate attention. Our study underscores inherent risks administration valuable insights its safe utilization patients.

Language: Английский

---

CALML6 as a potential diagnostic marker for thyroid cancer promotes thyroid cancer cell proliferation via modulating the immune microenvironment

Gene, Journal Year: 2024, Volume and Issue: 936, P. 149115 - 149115

Published: Nov. 19, 2024

Language: Английский

---